Sertraline HCl Clinical Trials

Size	Price	Qty
10mg	USD 70
50mg	USD 270

Clinical Trials

Sertraline hydrochloride has been evaluated in numerous clinical trials spanning Phase 1 safety assessments through Phase 4 post-marketing studies to investigate its pharmacokinetics, physiological impacts, and therapeutic potential. Research predominantly focuses on major depressive disorder, anxiety disorders, post-traumatic stress disorder, bipolar disorder, and depressive symptoms secondary to acute coronary syndrome or obesity. Sponsored by academic centers such as Columbia University and the University of Pennsylvania alongside industry entities like Pfizer and Viatris, these studies feature recruitment statuses ranging from recruiting and active to completed and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00262470	ACTIVE_NOT_RECRUITING	Tachycardia; Chronic Orthostatic Intolerance	Satish R. Raj	1997-04	PHASE1; PHASE2
NCT06704594	RECRUITING	Premenstrual Dysphoric Disorder (PMDD)	Johns Hopkins University	2025-05-14	PHASE4
NCT07645157	RECRUITING	Major Depressive Disorder (MDD); Probiotic Intervention	First Affiliated Hospital of Chongqing Medical University	2026-10-01	PHASE2
NCT06408246	RECRUITING	Depression	Stanford University	2026-03-03	PHASE2
NCT05973786	RECRUITING	Bipolar Depression	Dr. Inge Winter	2025-02-11	PHASE3
NCT05603104	RECRUITING	Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression	Dr. Inge Winter	2025-04-27	PHASE3
NCT07539805	RECRUITING	Major Depressive Disorder (MDD); Probiotic Intervention	First Affiliated Hospital of Chongqing Medical University	2026-06-11	PHASE2
NCT06384209	RECRUITING	Major Depressive Disorder; Severe Depressive Episode Without Psychotic Symptoms	University of Bern	2025-06-26
NCT07478796	RECRUITING	Depression - Major Depressive Disorder; Depressive Episodes	Poznan University of Medical Sciences	2025-04-03	PHASE4
NCT07318181	RECRUITING	Post Traumatic Stress Disorder; Post Traumatic Stress Disorder PTSD; Post-Traumatic Stress Disorder, PTSD	University of Luxembourg	2026-01-01
NCT06081348	RECRUITING	Neurodevelopmental Disorders; Autism; Autism Spectrum Disorder; Fragile X Syndrome; Tuberous Sclerosis; 22Q11 Deletion Syndrome; 22Q11 Deletion; ADHD; Tic Disorders; Tourette Syndrome; Tourette Syndrome in Children; Tourette Syndrome in Adolescence; ADHD - Combined Type; ADHD Predominantly Inattentive Type; ADHD, Predominantly Hyperactive - Impulsive; Anxiety; Anxiety Disorders	Holland Bloorview Kids Rehabilitation Hospital	2024-09-16	PHASE2
NCT05892744	RECRUITING	Major Depressive Disorder; Chronic Major Depression, Recurrent	University of Texas at Austin	2023-09-30	PHASE4
NCT07139834	RECRUITING	Major Depressive Disorder (MDD)	Jeffrey Miller	2026-06-01	PHASE1
NCT05683223	RECRUITING	Social Anxiety Disorder	Boston University Charles River Campus	2023-05-26
NCT04539951	RECRUITING	Obsessive-Compulsive Disorder	Shanghai Mental Health Center	2020-09-22	PHASE2
NCT07011693	NOT_YET_RECRUITING	Major Depressive Disorder (MDD)	Xinyu Zhou	2025-06-20	PHASE4
NCT07574060	RECRUITING	Depression	Tanta University	2026-05-20	PHASE2; PHASE3
NCT05273996	ACTIVE_NOT_RECRUITING	Major Depressive Disorder; Neuroticism; Cognitive Change; Stress	David Steffens	2021-09-28	PHASE4
NCT07025590	RECRUITING	Cardiovascular Diseases (CVD); Depression Anxiety Disorder	Guangdong Provincial People's Hospital	2025-04-22
NCT05814640	RECRUITING	Depression; Sequestra	First Affiliated Hospital of Chongqing Medical University	2023-02-20	PHASE1; PHASE2
NCT06796946	NOT_YET_RECRUITING	Deprescription; Antidepressants	University of Huelva	2026-06	EARLY_PHASE1
NCT04637620	RECRUITING	Major Depressive Disorder	China Medical University Hospital	2017-06-01	PHASE2
NCT04221997	RECRUITING	Anxiety Disorders	University of Cincinnati	2019-11-01	PHASE4
NCT07192367	RECRUITING	Social Anxiety Disorder	Emine Kanmaz	2024-11-15	PHASE4
NCT06827431	NOT_YET_RECRUITING	Major Depressive Disorder (MDD)	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	2025-02-14	PHASE3
NCT06965569	COMPLETED	Treatment Resistant Depression	Alar Pharmaceuticals Inc.	2025-04-21	PHASE1
NCT02890212	SUSPENDED	Major Depression	University of Sao Paulo General Hospital	2005-08
NCT05537584	COMPLETED	Major Depressive Disorder	Mclean Hospital	2022-09-30	PHASE4
NCT06840379	ACTIVE_NOT_RECRUITING	Inflamation; Hemodialysis; End Stage Renal Disease on Hemodialysis (Diagnosis)	Nishtar Medical University	2024-10-15
NCT04183205	TERMINATED	Posttraumatic Stress Disorder; Major Depressive Disorder	VA Office of Research and Development	2019-09-11	PHASE4
NCT06698666	RECRUITING	Major Depressive Disorder; MDD	Ain Shams University	2022-10-01	PHASE3
NCT06725771	COMPLETED	Generalised Anxiety Disorder	Lin Xiaoqian	2022-09-01
NCT06357104	COMPLETED	COVID-19 Vaccine Adverse Reaction	Pachankis, Yang I., M.D.	2024-02-26	PHASE4
NCT04963257	UNKNOWN	OCD	Second Affiliated Hospital, Zhejiang University, School of Medicine	2020-01-01	PHASE4
NCT05646693	UNKNOWN	Tinnitus, Subjective; Tinnitus, Bilateral; Antioxidant Therapy; Psychiatric Drugs; Oxidative Stress; Inflammatory Cytokines; SSRI	University of Guadalajara	2022-12-01	PHASE2
NCT06025474	UNKNOWN	Burning Mouth Syndrome	Federico II University	2023-01-01	PHASE3
NCT06124417	COMPLETED	Efficacy, Team; Adverse Reaction to Drug	First Affiliated Hospital of Chongqing Medical University	2022-01-10	PHASE4
NCT05189977	TERMINATED	Post-traumatic Stress Disorder (PTSD)	Otsuka Pharmaceutical Development & Commercialization, Inc.	2022-09-07	PHASE1
NCT04174170	COMPLETED	Post Traumatic Stress Disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	2019-10-30	PHASE3
NCT04124614	COMPLETED	Post Traumatic Stress Disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	2019-10-17	PHASE3
NCT04388202	WITHDRAWN	Major Depressive Disorder	Alto Neuroscience	2020-10-15	PHASE4
NCT05588102	COMPLETED	Geriatric Depression; Cognitive Impairment	Capital Medical University	2021-05-18
NCT05730062	Not yet recruiting	Opioid Induced Respiratory Depression\|Depressive Disorder\|Anxiety Disorders	Leiden University Medical Center	2023-03-15	Phase 1
NCT03779789	COMPLETED	Major Depressive Disorder	Azienda Ospedaliera Universitaria Integrata Verona	2019-02-01	PHASE4
NCT03279471	COMPLETED	Autism Spectrum Disorder; Anxiety	University of California, Davis	2017-10-01	PHASE2
NCT05950061	COMPLETED	Major Depressive Disorder	KRL Hospital, Islamabad	2022-06-01	PHASE3
NCT05341843	COMPLETED	Uremic Pruritis	Alexandria University	2022-05-01	PHASE2
NCT04977544	UNKNOWN	Phobia	Second Affiliated Hospital, Zhejiang University, School of Medicine	2019-09-01
NCT05189977	Terminated	Post-traumatic Stress Disorder (PTSD)	Otsuka Pharmaceutical Development & Commercialization Inc.\|Iqvia Pty Ltd	2022-09-07	Phase 1
NCT02777372	COMPLETED	PMDD; Stress; Mood	Johns Hopkins University	2016-04-01	PHASE4
NCT04476030	COMPLETED	Depressive Disorder, Major	Biogen	2020-11-09	PHASE3
NCT02917122	TERMINATED	Parkinson Disease; Depression	National Cheng-Kung University Hospital	2015-08	PHASE1; PHASE2
NCT03852160	WITHDRAWN	Depressive Disorder, Treatment-Resistant	Janssen-Cilag International NV	2019-12-01	PHASE3
NCT03841474	UNKNOWN	Coronary Artery Disease; Depression; Cardiovascular Diseases	Klinički Bolnički Centar Zagreb	2021-03-01
NCT03434041	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2018-05-25	PHASE3
NCT04430556	UNKNOWN	Major Depressive Disorder; Anxiety Disorders	Hospital Universitario Dr. Jose E. Gonzalez	2018-07-01
NCT02891278	COMPLETED	Acute Myeloid Leukemia	Columbia University	2016-08-11	PHASE1
NCT03414931	COMPLETED	Depressive Disorder, Major	Chang Gung Memorial Hospital	2016-01	PHASE2
NCT02452983	TERMINATED	Myelodysplastic Syndromes	Gustavo Rivero	2015-05	PHASE1
NCT04094870	COMPLETED	Perinatal Depression; HIV-1-infection	University of North Carolina, Chapel Hill	2019-10-30	PHASE4
NCT04171193	UNKNOWN	Depressive Disorder, Major; Treatment Resistant Depression; Depressive Episode	University of Sao Paulo	2019-12	PHASE2
NCT02955719	COMPLETED	Depression; Anxiety; Mild Cognitive Impairment	Centre for Addiction and Mental Health	2016-03-30
NCT05210153	Recruiting	Depressive Disorder Major	University of Belgrade\|Clinical Centre of Serbia\|Institute of Mental Health Serbia\|Military Medical Academy Belgrade Serbia	2020-07-16	--
NCT03469128	COMPLETED	Psychologic Manipulation	British University In Egypt	2016-01-01	PHASE1
NCT04147000	Terminated	Overweight\|Depression\|Anxiety Disorders	Linkoeping University\|Örebro University Sweden	2020-01-01	--
NCT03068429	COMPLETED	Obsessive-Compulsive Disorder	University of Sao Paulo	2016-12-01	PHASE4
NCT02189213	TERMINATED	Generalized Anxiety Disorder; Separation Anxiety Disorder; Social Phobia	New York State Psychiatric Institute	2014-07
NCT00693849	UNKNOWN	Major Depressive Disorder	BRC Operations Pty. Ltd.	2008-09	PHASE4
NCT02185547	TERMINATED	Pregnancy; Moderate Depression	Katarina Wide	2016-02-21	PHASE4
NCT02655354	COMPLETED	Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease	University of Washington	2015-10
NCT02813447	TERMINATED	COPD; Anxiety; Depression; Stress; Interstitial Lung Disease	Duke University	2016-08
NCT02908334	WITHDRAWN	Coccidioidomycosis	University of California, San Francisco	2016-11	PHASE2
NCT04076371	COMPLETED	Schizophrenia	Beijing HuiLongGuan Hospital	2012-01
NCT03179839	COMPLETED	Obsessive-Compulsive Disorder	Shanghai Mental Health Center	2017-01-20
NCT03033069	COMPLETED	Stress Disorders, Post-Traumatic	Otsuka Pharmaceutical Development & Commercialization, Inc.	2017-01-26	PHASE2
NCT03711708	Completed	Healthy	Pfizer''s Upjohn has merged with Mylan to form Viatris Inc.\|Pfizer	2018-11-06	Phase 4
NCT02770378	COMPLETED	Glioblastoma	University of Ulm	2016-11	PHASE1; PHASE2
NCT02385799	COMPLETED	Autism Spectrum Disorder	Randi J. Hagerman, MD	2015-04	PHASE2
NCT02641652	UNKNOWN	Hypertension	University Hospital Olomouc	2017-11	PHASE4
NCT02269540	COMPLETED	Major Depressive Disorder	Centre for Addiction and Mental Health	2014-10	EARLY_PHASE1
NCT01703039	TERMINATED	Major Depressive Disorder	Brigham and Women's Hospital	2013-01	PHASE2
NCT03002012	TERMINATED	Cryptococcosis; Cryptococcal Infections; AIDS-Related Opportunistic Infections	University of Minnesota	2017-11-15	PHASE3
NCT02417064	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-08-10	PHASE3
NCT01305889	COMPLETED	Major Depressive Disorder	University of California, San Francisco	2011-03
NCT02493868	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2015-10-01	PHASE3
NCT03342963	COMPLETED	Healthy Male Adults	Otsuka Pharmaceutical Co., Ltd.	2017-11-21	PHASE1
NCT00182533	TERMINATED	Phobia, Social; Panic Disorder; Agoraphobia; Obsessive-Compulsive Disorder; Anxiety Disorders; Major Depressive Disorder	Hamilton Health Sciences Corporation	2002-07	PHASE4
NCT01427608	COMPLETED	Psychotic Depression	Weill Medical College of Cornell University	2011-10	PHASE4
NCT02022709	COMPLETED	Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders	Shanghai Mental Health Center	2014-01	PHASE4
NCT02358343	COMPLETED	Depression; End Stage Renal Disease	University of Washington	2015-03-23	PHASE3
NCT02497287	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-09-30	PHASE3
NCT03514810	COMPLETED	Major Depressive Disorder	Kufa University	2017-01-10	PHASE1
NCT01802385	COMPLETED	Cryptococcal Meningitis; Fungal Meningitis	University of Minnesota	2015-03-09	PHASE3
NCT02422186	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2015-08-20	PHASE3
NCT03978286	COMPLETED	Depression; Type 2 Diabetes Mellitus	Universidad Juárez Autónoma de Tabasco	2016-06-30	PHASE4
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT02418585	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-08-07	PHASE3
NCT01360866	COMPLETED	Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-10	PHASE3
NCT02739061	COMPLETED	Obsessive-Compulsive Disorder	Shanghai Mental Health Center	2014-06-12
NCT02797808	COMPLETED	OCD	University of Minnesota	2013-08	PHASE1; PHASE2
NCT01600456	COMPLETED	Posttraumatic Stress Disorder	Case Western Reserve University	2011-03	PHASE3
NCT02268487	UNKNOWN	Major Depressive Disorder	University of Sao Paulo	2014-01	PHASE4
NCT01524133	COMPLETED	Posttraumatic Stress Disorder	VA Ann Arbor Healthcare System	2011-11	PHASE4
NCT00946998	COMPLETED	Chronic Kidney Disease; Depression	VA Office of Research and Development	2010-02-08	PHASE3
NCT02520726	TERMINATED	Post-traumatic Stress Disorder	University of Utah	2013-09	PHASE4
NCT02651623	COMPLETED	Healthy	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2016-01	PHASE1
NCT02504931	COMPLETED	PTSD; Alcohol Use Disorder	The University of Texas Health Science Center at San Antonio	2011-04	PHASE4
NCT02228005	COMPLETED	Depression	University Health Network, Toronto	2014-07	PHASE4
NCT01896934	COMPLETED	Major Depressive Disorder	Vanderbilt University	2013-07	PHASE4
NCT01856127	TERMINATED	Sexual Dysfunction; Major Depressive Disorder	Thomas Jefferson University	2013-01	PHASE4
NCT01407094	COMPLETED	Depression	University of Texas Southwestern Medical Center	2011-07-29	PHASE2
NCT02469545	COMPLETED	Depression; Anxiety Disorder	Medical University of Bialystok	2014-06	PHASE2
NCT02347033	TERMINATED	Generalised Anxiety Disorder	University College, London	2014-08	PHASE4
NCT02463110	TERMINATED	Depression; Coronary Artery Disease	Assistance Publique - Hôpitaux de Paris	2015-07	PHASE4
NCT01987960	TERMINATED	Post-traumatic Stress Disorder; PTSD	H. Lundbeck A/S	2013-12	PHASE3
NCT01109693	COMPLETED	Unipolar Major Depressive Episode	Kyoto University	2010-12	PHASE4
NCT01474746	COMPLETED	Fragile X Syndrome	Randi J. Hagerman, MD	2012-01	PHASE2
NCT02235064	TERMINATED	Depression, Postpartum	The Cooper Health System	2014-07
NCT02565316	COMPLETED	Depression; Anxiety	Shiraz University of Medical Sciences	2014-11	PHASE2; PHASE3
NCT01794455	TERMINATED	Depression; Hypertension	Vanderbilt University	2013-05	PHASE4
NCT02237937	UNKNOWN	Major Depression	HolsboerMaschmeyer NeuroChemie GmbH	2011-09	PHASE4
NCT02918097	COMPLETED	Bipolar Disorder	Federal University of Rio Grande do Sul	2010-05	PHASE4
NCT02901249	COMPLETED	Depression	Federal University of Rio Grande do Sul	2010-05	PHASE4
NCT01669304	COMPLETED	Vestibular Migraine; Chronic Subjective Dizziness	Mayo Clinic	2012-08	PHASE1
NCT01569685	COMPLETED	Post Traumatic Stress Disorder; Depression	Charlotte Sonne	2012-04	PHASE4
NCT01764867	UNKNOWN	Major Depressive Disorder	Shanghai Mental Health Center	2012-06	PHASE4
NCT01977729	TERMINATED	Anxiety Disorder of Adolescence	Yale University	2013-10	PHASE2
NCT02175602	COMPLETED	Hepatitis C Infection	Bristol-Myers Squibb	2014-06	PHASE1
NCT01896349	UNKNOWN	Treatment Resistant Depression	Hospital de Clinicas de Porto Alegre	2013-04
NCT01214382	COMPLETED	Roux en Y Gastric Bypass Surgery	North Dakota State University	2010-10	PHASE3
NCT00602355	COMPLETED	Depression, Postpartum	Women and Infants Hospital of Rhode Island	2008-02	PHASE2
NCT01178671	COMPLETED	Posttraumatic Stress Disorder	Research Foundation for Mental Hygiene, Inc.	2010-07	PHASE4
NCT00704379	COMPLETED	Traumatic Brain Injury	Baylor College of Medicine	2008-06	PHASE2; PHASE3
NCT02179268	COMPLETED	Bone Mineral Density Quantitative Trait Locus 7	Guiyang Medical University	2012-03	PHASE3
NCT00917397	COMPLETED	Post-Traumatic Stress Disorder	Caecilie Buhmann	2009-06	PHASE4
NCT01287494	UNKNOWN	Depression	Zhejiang University	2010-08	PHASE4
NCT01027559	COMPLETED	Major Depression; Treatment	Washington University School of Medicine	2009-02
NCT02088697	COMPLETED	Healthy Volunteers	Otsuka Pharmaceutical Co., Ltd.	2013-12	PHASE1
NCT01769027	WITHDRAWN	Pandas	CNS Onlus	2013-06	PHASE2
NCT00744328	TERMINATED	Postpartum Depression	Northwestern University	2008-08	PHASE4
NCT01437189	COMPLETED	Depression; Parkinson's Disease	Zhejiang University	2011-08-01
NCT01751828	WITHDRAWN	Depression	Vanderbilt University	2012-12
NCT00262223	COMPLETED	Stress Disorders, Post-Traumatic; Alcohol Abuse; Substance-Related Disorders	New York State Psychiatric Institute	2006-05	PHASE2
NCT01098318	COMPLETED	Depression	University of Pennsylvania	2010-06	PHASE3
NCT00834652	COMPLETED	Depression	Washington University School of Medicine	2007-09	PHASE4
NCT00531518	COMPLETED	Schizophrenia; Bipolar Disorder; Depression; Psychotic Disorders	MaineHealth	2007-10
NCT00178828	COMPLETED	Depression	Vanderbilt University Medical Center	2002-10	PHASE4
NCT00955474	TERMINATED	Major Depressive Disorder With Psychotic Features	Massachusetts General Hospital	2008-09	PHASE4
NCT00835627	COMPLETED	Convulsion, Non-Epileptic; Conversion Disorder; Depression; Stress Disorders, Post-Traumatic; Dissociative Disorders	Rhode Island Hospital	2008-09	PHASE4
NCT01309074	WITHDRAWN	Epilepsy; Anxiety	Rush University Medical Center	2009-11	PHASE4
NCT02473783	COMPLETED	Major Depressive Disorder	Tri-Service General Hospital (TSGH)	2011-10	PHASE2
NCT01467804	UNKNOWN	Depressive Disorder	Su Rui	2011-11
NCT01699724	COMPLETED	Healthy	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2012-09	PHASE1
NCT01254305	COMPLETED	Major Depressive Disorder	Forest Laboratories	2011-04	PHASE2
NCT01032434	COMPLETED	Depression	Guang Dong Provincial Mental Health Institute	2009-12
NCT00276965	COMPLETED	Bipolar Disorder; Depression	Lindner Center of HOPE	2006-09	PHASE3
NCT01113164	COMPLETED	Alcoholism	Brown University	2008-09	PHASE1
NCT00536198	COMPLETED	Premenstrual Dysphoric Disorder	Yale University	2007-11-06	PHASE4
NCT01032018	COMPLETED	Acute Coronary Syndrome; Depression	Columbia University	2010-01	PHASE1; PHASE2
NCT00581009	COMPLETED	Major Depressive Disorder; Bipolar Disorder	University of California, Irvine	2001-05-30	PHASE1; PHASE2
NCT00282828	COMPLETED	Social Phobia	Massachusetts General Hospital	2006-03	PHASE4
NCT01033084	COMPLETED	Depressive Disorder, Major	University of Sao Paulo	2009-12	PHASE2; PHASE3
NCT00127673	COMPLETED	Post-Traumatic Stress Disorder	Case Western Reserve University	2004-09	PHASE3
NCT00302068	COMPLETED	Depression; Heart Diseases	Duke University	2006-07	PHASE3
NCT00857584	COMPLETED	Bipolar Disorder; Bipolar Depression	AstraZeneca	2009-05	PHASE3
NCT01250873	COMPLETED	Major Depressive Disorder	Eli Lilly and Company	2010-11	PHASE1
NCT01235195	COMPLETED	Healthy	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2010-11	PHASE1
NCT00519012	UNKNOWN	Depression	Oizumi Hospital	2007-08	PHASE4
NCT00594269	COMPLETED	Dementia	Sykehuset Innlandet HF	2008-08	PHASE4
NCT01028482	COMPLETED	Postpartum Depression	Tel-Aviv Sourasky Medical Center	2008-03
NCT01155531	COMPLETED	Obesity	Theracos	2010-05	PHASE1
NCT00612807	COMPLETED	Major Depressive Disorder; Partner Relational Disorder (V61.10)	Duke University	2006-07	PHASE1; PHASE2
NCT01454635	COMPLETED	Major Depressive Disorder	Showa University	2008-06
NCT00510822	COMPLETED	Major Depression	Affectis Pharmaceuticals AG	2007-10	PHASE2
NCT00677352	COMPLETED	Panic Disorder	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2008-05	PHASE4
NCT00969852	COMPLETED	Healthy	Seoul National University Hospital	2009-07	PHASE4
NCT00701675	COMPLETED	Generalized Anxiety Disorder	VA Office of Research and Development	2005-10	PHASE4
NCT00391430	TERMINATED	Post-Traumatic Stress Disorder	NYU Langone Health	2005-05	PHASE4
NCT00116857	COMPLETED	Cardiovascular Diseases; Depression; Heart Diseases; Myocardial Infarction; Angina, Unstable	Washington University School of Medicine	2005-02	PHASE3
NCT00043550	COMPLETED	Depression	University of Pennsylvania	2001-11	PHASE3
NCT00368550	COMPLETED	Alcoholism	UConn Health	2004-02	PHASE4
NCT00654953	COMPLETED	Cocaine Dependence; Depressive Symptoms	University of Arkansas	2006-01	PHASE2
NCT00232284	COMPLETED	Depression; Substance-Related Disorders	Dan Lubman	2004-09	PHASE2
NCT00873795	COMPLETED	Major Depressive Disorder	Chimei Medical Center	2007-04
NCT00666757	COMPLETED	Depression	Eli Lilly and Company	2008-05	PHASE4
NCT00208117	TERMINATED	Depression; Coronary Artery Disease (CAD); Acute Coronary Syndrome (ACS)	New York State Psychiatric Institute	2005-04	PHASE1
NCT00215150	COMPLETED	Social Anxiety Disorder	Duke University	2004-11	PHASE2
NCT00624013	COMPLETED	Diabetes; Depression	Charles Drew University of Medicine and Science	2006-09	PHASE4
NCT00233103	COMPLETED	Depression	Icahn School of Medicine at Mount Sinai	2003-06	PHASE2
NCT00680602	COMPLETED	Obsessive Compulsive Disorder	University of Sao Paulo	2006-01	PHASE4
NCT00245557	COMPLETED	Major Depressive Disorder	Mclean Hospital	2004-11
NCT00086138	COMPLETED	Alzheimer's Disease; Depression	Johns Hopkins University	2004-07	PHASE2; PHASE3
NCT00159965	COMPLETED	Convulsion, Non-Epileptic; Conversion Disorder; Depression; Stress Disorders, Post-Traumatic	Rhode Island Hospital	2003-12	PHASE4
NCT00056472	COMPLETED	Major Depressive Disorder With Psychotic Features	Weill Medical College of Cornell University	2003-01	PHASE3
NCT00078286	COMPLETED	Heart Failure, Congestive; Chronic Heart Failure; Depression	Duke University	2003-11	PHASE2; PHASE3
NCT00318773	COMPLETED	Premenstrual Syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2002-02	PHASE4
NCT00299611	TERMINATED	Obsessive-Compulsive Disorder	Duke University	2005-11	PHASE2; PHASE3
NCT00052078	COMPLETED	Anxiety Disorders; Social Phobia; Generalized Anxiety Disorder	Johns Hopkins University	2003-01	PHASE3
NCT00118417	COMPLETED	Panic Disorder	Massachusetts General Hospital	1999-03	PHASE2; PHASE3
NCT00177424	TERMINATED	Cerebrovascular Accident; Depression	University of Pittsburgh	2004-07	PHASE4
NCT00048854	COMPLETED	Premenstrual Syndrome	Yale University	2001-09	PHASE1; PHASE2
NCT00375843	COMPLETED	Depression	National Institute of Mental Health (NIMH)	2005-01	PHASE4
NCT00026637	COMPLETED	Depression; Epilepsy	Columbia University	2001-08	PHASE3
NCT00284791	TERMINATED	Adolescent Depression	MaineHealth	2006-01
NCT00177996	COMPLETED	Major Depression	University of Pittsburgh	2001-10	PHASE4
NCT00009191	COMPLETED	Alzheimer Disease; Depression	Johns Hopkins University	2005-11	PHASE4
NCT00234312	COMPLETED	Depression; Dysthymia	Oregon Health and Science University	2005-09	PHASE4
NCT01267383	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-09	PHASE1
NCT01267396	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-09	PHASE1
NCT00133822	COMPLETED	Post-Traumatic Stress Disorders	Emory University	2004-04	PHASE1; PHASE2
NCT00655174	COMPLETED	Autism	The Hospital for Sick Children	1999-06	PHASE3
NCT00744406	COMPLETED	Depression; Major Depressive Disorder	Centre for Addiction and Mental Health	2003-07	PHASE2
NCT00057642	COMPLETED	Depression; Depressive Disorder	New York State Psychiatric Institute	2002-09
NCT00276900	COMPLETED	Depression	University of Pittsburgh	2003-12	PHASE3
NCT00182078	COMPLETED	Posttraumatic Stress Disorder; Depression	Massachusetts General Hospital	2002-11	PHASE4
NCT00078767	COMPLETED	Stress Disorders, Post-Traumatic	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	2001-04	PHASE3
NCT00229476	COMPLETED	Depressive Disorder, Major	University of California, Los Angeles	2003-12	PHASE4
NCT00339066	COMPLETED	Depression	Duke University	2001-08
NCT00249431	TERMINATED	Alcoholism; Gambling	New York State Psychiatric Institute	2001-12	PHASE2
NCT00778973	COMPLETED	Healthy	Ranbaxy Laboratories Limited	2005-08
NCT00004554	COMPLETED	Alcoholism; Depression	University of Pennsylvania	2000-01	PHASE4
NCT00340379	COMPLETED	Affective Disorders	Duke University	2003-04	PHASE2; PHASE3
NCT00779350	COMPLETED	Healthy	Ranbaxy Laboratories Limited	2005-08
NCT00000451	COMPLETED	Alcoholism; Alcohol Dependence	Yale University	2003-01	PHASE2
NCT00066859	COMPLETED	Depression; Unspecified Adult Solid Tumor, Protocol Specific	Wake Forest University Health Sciences	2004-03-01	PHASE3
NCT02122393	COMPLETED	Depression; Anxiety	University of Melbourne	2002-04	PHASE3
NCT00864019	COMPLETED	Healthy	Actavis Inc.	2004-08	PHASE1
NCT00864344	COMPLETED	Healthy	Actavis Inc.	2004-08	PHASE1
NCT00118014	COMPLETED	Impulse Control Disorders	Massachusetts General Hospital	2000-01	PHASE4
NCT00602849	COMPLETED	Depression	Roxane Laboratories	2003-06
NCT00601588	COMPLETED	Depression	Roxane Laboratories	2003-06
NCT00208702	COMPLETED	Major Depression	Emory University	1996-09	PHASE4
NCT01114100	COMPLETED	Panic Attacks; Chest Pain; Depression	Maastricht University Medical Center	2000-01	PHASE4
NCT00650325	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2002-11	PHASE1
NCT00648856	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2002-12	PHASE1
NCT00000378	COMPLETED	Depression; Melancholia	New York State Psychiatric Institute	1997-07	PHASE4
NCT00836849	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-03	PHASE1
NCT00836667	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-03	PHASE1
NCT00015132	COMPLETED	Cocaine-Related Disorders	National Institute on Drug Abuse (NIDA)	1999-03	PHASE2
NCT00491478	UNKNOWN	Mental Retardation; Stereotyped Behavior; Self-Injurious Behavior; Compulsive Behavior	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1992-09	PHASE3
NCT00374426	COMPLETED	Major Depression; Diabetes	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1998-03	PHASE4
NCT00406952	COMPLETED	Depressive Disorder, Major	Pfizer	2006-11
NCT00283192	COMPLETED	Menopause-Hot Flashes	University of California, San Francisco	2003-07
NCT00325000	TERMINATED	Major Depression	German Research Foundation	2000-11
NCT00263133	COMPLETED	Depression	University Hospital Freiburg	2005-12
NCT00208585	UNKNOWN	Traumatic Brain Injury	Walter Reed Army Medical Center	2000-02
NCT00215241	COMPLETED	Post-Traumatic Stress Disorder	Duke University	2004-04	PHASE2; PHASE3
NCT00331305	COMPLETED	Depression	Duke University	1999-08	PHASE3
NCT00058903	COMPLETED	Pruritus; Liver Cirrhosis, Biliary; Hepatitis C	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2003-04	PHASE2
NCT00198094	COMPLETED	Panic Disorder	Indiana University	2003-12	PHASE4
NCT00158990	COMPLETED	Major Depression; Bipolar Disorder; Unipolar Depression	Hadassah Medical Organization	2002-10	PHASE3
NCT00169988	COMPLETED	Prodromal Schizophrenia; Psychotic Disorders	Northwell Health	2004-03
NCT00944242	COMPLETED	Healthy	Torrent Pharmaceuticals Limited		PHASE1
NCT00001777	COMPLETED	Dementia	National Institute of Neurological Disorders and Stroke (NINDS)	1997-12	PHASE1
NCT00508859	COMPLETED	Depression	Sunnybrook Health Sciences Centre	1997-07	PHASE4
NCT00050804	COMPLETED	Acute Traumatic Stress Disorders; Post-Traumatic Stress Disorders	National Institute of Mental Health (NIMH)	2002-12	PHASE4
NCT00000384	COMPLETED	Obsessive-Compulsive Disorder	University of Pennsylvania	1997-05	PHASE3
NCT00000458	COMPLETED	Alcoholism; Depression	National Institute on Alcohol Abuse and Alcoholism (NIAAA)		PHASE2
NCT00000440	COMPLETED	Alcoholism	National Institute on Alcohol Abuse and Alcoholism (NIAAA)		PHASE2
NCT00080158	COMPLETED	Depression; Suicide, Attempted	New York State Psychiatric Institute	2004-03	PHASE2; PHASE3
NCT00644982	COMPLETED	Depressive Disorder, Major	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2002-10	PHASE4
NCT00150306	TERMINATED	Stress Disorders, Post-Traumatic	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2002-11	PHASE3
NCT00001483	COMPLETED	Bipolar Disorder; Depressive Disorder	National Institute of Mental Health (NIMH)	1995-06	PHASE2
NCT00000446	COMPLETED	Alcoholism; Post-Traumatic Stress Disorder	National Institute on Alcohol Abuse and Alcoholism (NIAAA)		PHASE2
NCT00636246	COMPLETED	Depressive Disorder, Major	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2004-06	PHASE2
NCT00275197	COMPLETED	Depressive Disorder, Major	Pfizer	2005-12	PHASE2
NCT00174590	TERMINATED	Major Depression With Psychotic Features	Rush University Medical Center	2001-09	PHASE3
NCT00179257	COMPLETED	Major Depressive Disorder	Vanderbilt University	2004-06	PHASE3
NCT00351910	COMPLETED	Major Depressive Disorder	AstraZeneca	2006-05	PHASE3
NCT00485862	COMPLETED	Depressive Symptoms	Eli Lilly and Company	2003-06	PHASE4
NCT00021528	COMPLETED	Depression	National Institute of Mental Health (NIMH)	2001-07	PHASE4
NCT00946036	COMPLETED	Healthy	Torrent Pharmaceuticals Limited		PHASE1
NCT00005013	COMPLETED	Major Depression	National Institute of Mental Health (NIMH)	1998-12
NCT00232167	TERMINATED	Insomnia; Depression	Neurocrine Biosciences	2005-11	PHASE3
NCT00143091	TERMINATED	Depressive Disorder, Major	Pfizer	2005-04	PHASE2
NCT00179283	COMPLETED	Major Depressive Disorder	Vanderbilt University	2002-04	PHASE3
NCT00421369	COMPLETED	Major Depressive Disorder	Hadassah Medical Organization	2007-09
NCT00004300	SUSPENDED	Stereotyped Behavior; Mental Retardation	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		PHASE2

(data from https://clinicaltrials.gov, updated on 2025-10-08)

Check the Sertraline HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Sertraline HCl acts as a 5-HT antagonist with an affinity Ki of 13 nM, binding serotonin targets to attenuate downstream serotonergic biochemical cascades and alter synaptic neurotransmission. This modulation of central signaling pathways reduces neuronal hyperresponsiveness and restores emotional signaling networks, supporting its therapeutic activity in major depressive disorder, anxiety disorders, and post-traumatic stress disorder.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).